NorthWest Biotherapeutics Inc (NWBO)

[alexander77]

Read this (unbiased,makes me bullish): "Despite the highly promising data, many key opinion leaders (KOLs) interviewed by GlobalData had mixed views about the dendritic cell vaccine. KOLs noted that Northwest Bio’s data was presented in an unusual way for a randomised Phase III trial and the criteria for selection was highly meticulous with an estimated 1,599 patients screened and 1,268 of these patients excluded from the trial. It is speculated that only the patients expected to live longer were included in the study due to the scrupulous selection criteria, which could have led to bias in the dataset.

Despite some skepticism, other KOLs did have positive opinions about the data. DCVax-L is unique because it doesn’t target one particular antigen, but uses the patient’s own tumour specimen to create the vaccine. Even assuming an FDA approval, KOLs mentioned that the personalised vaccine may suffer challenges in terms of preparation of the vaccine. The logistics and requirements for creating such a personalised vaccine would be a barrier for DCVax-L being adopted in routine clinical practice."

https://www.pharmaceutical-technology.com/comment/northwest-bios-dcvax-l-hype-warranted-glioblastoma-patients/